These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 9358470)
1. Idiotypic vaccination in B-cell malignancies. Bianchi A; Massaia M Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470 [TBL] [Abstract][Full Text] [Related]
2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
3. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Fredriksen AB; Sandlie I; Bogen B Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of hematological malignancies using dendritic cells. Van de Velde AL; Berneman ZN; Van Tendeloo VF Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412 [TBL] [Abstract][Full Text] [Related]
6. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies. Leitch HA; Connors JM Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in multiple myeloma: current strategies and future prospects. Yi Q Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804 [TBL] [Abstract][Full Text] [Related]
10. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. King CA; Spellerberg MB; Zhu D; Rice J; Sahota SS; Thompsett AR; Hamblin TJ; Radl J; Stevenson FK Nat Med; 1998 Nov; 4(11):1281-6. PubMed ID: 9809552 [TBL] [Abstract][Full Text] [Related]
11. Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders. Milosević DB J Exp Clin Cancer Res; 2004 Mar; 23(1):9-13. PubMed ID: 15149145 [TBL] [Abstract][Full Text] [Related]
12. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733 [TBL] [Abstract][Full Text] [Related]
13. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Kwak LW; Campbell M; Levy R Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139 [TBL] [Abstract][Full Text] [Related]
14. The role of idiotype vaccines in the treatment of human B-cell malignancies. Bendandi M Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042 [TBL] [Abstract][Full Text] [Related]
15. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth. Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709 [TBL] [Abstract][Full Text] [Related]
16. DNA vaccination: antigen presentation and the induction of immunity. Shedlock DJ; Weiner DB J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646 [TBL] [Abstract][Full Text] [Related]
18. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465 [TBL] [Abstract][Full Text] [Related]
19. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Flamand V; Sornasse T; Thielemans K; Demanet C; Bakkus M; Bazin H; Tielemans F; Leo O; Urbain J; Moser M Eur J Immunol; 1994 Mar; 24(3):605-10. PubMed ID: 8125131 [TBL] [Abstract][Full Text] [Related]
20. Antitumor vaccination: where we stand. Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]